Tata Elxsi Q3 Results: Profit Falls 13%, Misses Estimates
Tata Elxsi Ltd.'s consolidated net profit fell 13% sequentially in the third quarter of the current financial year, missing analysts' estimates.
The design and technology provider posted a profit of Rs 199 crore in the quarter ended December, according to an exchange filing. Analysts tracked by Bloomberg had a consensus estimate of Rs 216 crore.
Tata Elxsi Q3 FY25 Highlights (Consolidated, QoQ)
Revenue down 1.7% to Rs 939.2 crore versus Rs 955.1 crore (Bloomberg estimate: Rs 987 crore).
EBIT down 8% to Rs 220.6 crore versus Rs 239.3 crore (Estimate: Rs 259 crore).
Margin narrows to 23.5% versus 25.1% (Estimate: 26.3%).
Net profit down 13% to Rs 199 crore versus Rs 229.4 crore (Estimate: 216 crore).
The automotive industry has seen significant business challenges in the past few months, with the original equipment manufacturers, especially in the US and Europe, reporting sales and growth challenges. This has impacted new deal closures and Tier 1 supplier spend, according to Chief Executive Officer Manoj Raghavan.
"Amid this business environment, Tata Elxsi continues to do well to win and execute on the large deals won over this year and demonstrate differentiated value to customers, to protect and grow revenues in a difficult quarter for the entire automotive industry," Raghavan added.
Shares of Tata Elxsi closed 0.52% lower at Rs 6,439.95 apiece on the National Stock Exchange, compared to a 0.69% fall in the benchmark Nifty. The share price has fallen 25.49% in the last 12 months.
Out of 14 analysts tracking the company, three maintain a 'buy' rating on the stock and 11 recommend 'sell', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 3.2%.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.